Furthermore, rapamycin doses aimed at slowing or reversing ageing are generally even lower than those used for immunosuppression and cancer treatment (Bitto et al., 2016; Bjedov et al., 2010; Castillo‐Quan et al., 2019; Fok et al., 2014; Harrison et al., 2009; Robida‐Stubbs et al., 2012; Schinaman et al., 2019), further suggesting that TRPML1 activation is unlikely to be involved in rapamycin‐mediated lifespan extension. The gene discussed is MCOLN1; the disease is cancer.